High-yield points
- Autosomal dominant; two thirds de novo.
- TSC1/TSC2 loss causes mTORC1 overactivity.
- A pathogenic variant alone is diagnostic. Mosaicism is possible .
- Diagnosis: 2 major features, or 1 major plus 2 or more minor .
- Brain causes the most morbidity; kidney causes the most deaths .
- The brain trio: tubers 82%, subependymal nodules 78%, SEGA about 25% (more with TSC2) .
- Epilepsy in 70–90%. Screen infants with EEG .
- Rhabdomyomas: a prenatal clue that regresses .
- Angiomyolipomas:
- an mTOR inhibitor if over 4 cm (or rapidly growing and over 3 cm);
- embolization plus steroids for bleeding;
- avoid nephrectomy .
- LAM in adult women: sirolimus stabilizes FEV1. Avoid estrogen and smoking .
- Workup at diagnosis: genetics, brain MRI and EEG, TAND screen, eye examination, echocardiogram and ECG, abdominal MRI with BP and GFR, chest CT in adult women, skin and dental examination .
Landmark papers
- Updated international TSC criteria (Northrup et al., Pediatr Neurol 2021): definite TSC is 2 major features, or 1 major plus 2 or more minor features, or a pathogenic variant. The 2021 update made only two changes to the clinical criteria .
- EXIST-2 (Bissler et al., Lancet 2013): a randomized, placebo-controlled trial in 118 adults with angiomyolipomas of 3 cm or more. A 50% or greater volume reduction occurred in 42% with everolimus vs 0% with placebo .
- MILES (McCormack et al., N Engl J Med 2011): sirolimus in 89 patients with lymphangioleiomyomatosis and moderate impairment stabilized FEV1 (+1 vs −12 mL per month on placebo), and the decline resumed after stopping .
Tuberous sclerosis complex (TSC) is inherited in an autosomal dominant pattern. It affects many organ systems and varies widely in presentation .
- Cause: loss of TSC1 (hamartin) or TSC2 (tuberin) leaves mTOR constitutively active, so benign tumors grow in the brain, kidney, heart, skin and lung .
- What drives outcomes: central nervous system problems, including neuropsychiatric disorders, are the leading cause of morbidity; kidney disease is the leading cause of mortality .
- Related topics:
- subependymal giant cell astrocytoma (SEGA): see the SEGA topic in the Pediatric Neuro-Oncology section;
- drug-resistant epilepsy: see the TSC epilepsy topic in the Epilepsy and Movement Disorder Surgery section.
Genetics
- Genes: TSC1 (chromosome 9q34, hamartin) and TSC2 (16p13.3, tuberin). Their products form a complex that restrains mTORC1 (see caveats).
- Inheritance :
- autosomal dominant;
- about one third of people with TSC have an affected parent; two thirds have a de novo variant;
- each child of an affected person has a 50% chance of inheriting the variant.
- Genetic diagnosis: a pathogenic variant in TSC1 or TSC2 is diagnostic on its own, even without clinical features .
- Mosaicism: some people are genetically mosaic . They may have milder disease and negative blood testing, so testing affected tissue can help (see caveats).
- Genotype and phenotype:
- TSC2 variants cause more severe disease. SEGA is more frequent with TSC2 than TSC1 (33.7% vs 13.2%) .
- Every child with drug-resistant epilepsy in a prospective cohort enrolled by age 6 months had a TSC2 variant .
- Severe early polycystic kidney disease: a large deletion spanning TSC2 and the adjacent PKD1 gene causes it (contiguous gene syndrome; see caveats).
- Family testing: evaluate at-risk relatives, including children, so they can start surveillance early. Predictive and prenatal or preimplantation testing is possible once the family variant is known .
Clinical diagnosis (2021 international criteria)
- Definite TSC = 2 major features, or 1 major plus 2 or more minor features, or a pathogenic variant .
- The 2021 update made only two changes to the clinical criteria :
- "multiple cortical tubers and/or radial migration lines" replaced "cortical dysplasias";
- sclerotic bone lesions returned to the minor criteria.
- Major features (see caveats):
- Skin:
- 3 or more hypomelanotic macules of at least 5 mm;
- 3 or more angiofibromas, or a fibrous cephalic plaque;
- 2 or more ungual fibromas;
- shagreen patch.
- Eye: multiple retinal hamartomas.
- Brain:
- multiple cortical tubers and/or radial migration lines;
- 2 or more subependymal nodules;
- SEGA.
- Heart: cardiac rhabdomyoma.
- Lung: lymphangioleiomyomatosis (LAM).
- Kidney: 2 or more angiomyolipomas.
- LAM plus angiomyolipomas without other features is not enough for a definite diagnosis.
- Minor features (see caveats):
- "confetti" skin lesions;
- 3 or more dental enamel pits;
- 2 or more intraoral fibromas;
- retinal achromic patch;
- multiple renal cysts;
- non-renal hamartomas;
- sclerotic bone lesions.
Organ systems
Brain and behavior
- How common (TOSCA registry, 2,093 patients) :
- cortical tubers 82.2%;
- subependymal nodules 78.2%;
- SEGA 24.4%.
- Epilepsy: develops in 70–90% of children with TSC and is often drug-resistant .
- Infantile spasms are the classic early presentation.
- SEGA: found in 25% of registry patients .
- Median age at diagnosis was 8 years, but SEGAs can appear and grow in adults.
- Symptoms (42.1% of patients with SEGA) include more seizures, behavioral change and regression, as well as raised ICP .
- TSC-associated neuropsychiatric disorders (TAND):
- autism, ADHD, intellectual disability, anxiety and behavioral problems;
- the 2021 update strengthened their surveillance and management .
- Hydrocephalus: almost always obstructive, from a SEGA at the foramen of Monro.
Skin and mouth
- Facial angiofibromas: occur in about 75% .
- Topical rapamycin 1% gave clinically meaningful improvement. End-of-treatment photos were rated "better" in 81.8% vs 25.5% with vehicle, with no measurable systemic absorption .
- Other skin and mouth findings :
- hypomelanotic (ash-leaf) macules, best seen under a Wood's lamp in infants;
- "confetti" lesions;
- shagreen patch;
- fibrous cephalic (forehead) plaque;
- ungual fibromas;
- dental enamel pits and intraoral fibromas (minor criteria ).
Eye
- Paediatric cohort (50 children) :
- retinal astrocytic hamartomas in 34% and achromic patches in 34%;
- refractive errors in 62%, strabismus in 16%.
- Vigabatrin retinal toxicity: of 10 children on vigabatrin tested with electroretinography, treatment had to be reduced or stopped in 3. Retinal function needs monitoring .
Heart
- Cardiac rhabdomyomas:
- the commonest paediatric cardiac tumor, strongly associated with TSC ;
- often seen prenatally, and frequently the first clue to TSC (see caveats).
- Natural history: slow regression. Without significant mass effect or arrhythmia in early childhood, the cardiac prognosis is good .
- Arrhythmia: documented in 18% of children with benign cardiac tumors; half of those needed beta-blockade .
- Treatment: mTOR inhibitors should be considered for rhabdomyomas causing obstruction or rhythm problems .
Kidney: the leading cause of death
- Lesions :
- angiomyolipomas (47.2% in TOSCA );
- epithelial cysts;
- oncocytoma;
- renal cell carcinoma.
- Risks: angiomyolipomas grow insidiously and can cause retroperitoneal hemorrhage and loss of renal function .
- Everolimus (EXIST-2) :
- 118 adults with angiomyolipomas of 3 cm or more (TSC or sporadic LAM);
- 42% response (50% or greater volume reduction) vs 0% on placebo;
- the commonest side effect was stomatitis (48%).
- Indications for treatment :
- mTOR inhibitor first-line for angiomyolipomas over 4 cm, or rapidly growing ones over 3 cm;
- embolization followed by corticosteroids for acute hemorrhage;
- avoid nephrectomy.
Lung
- LAM:
- a progressive cystic lung disease, chiefly in women;
- 6.9% in TOSCA , rising with age (see caveats);
- other lung findings include multifocal micronodular pneumocyte hyperplasia .
- Sirolimus (MILES) :
- 89 patients with moderate impairment;
- stabilized FEV1: +1 vs −12 mL per month on placebo;
- the decline resumed after stopping.
- Avoid smoking and estrogen .
Other organs
- Sclerotic bone lesions (a minor criterion) .
- Non-renal hamartomas: liver angiomyolipomas, for example.
- Neuroendocrine tumors: managed by endocrinology .
Workup at diagnosis
Based on the international recommendations and GeneReviews ; see caveats.
- Genetics:
- genetic counseling and TSC1/TSC2 testing;
- test affected tissue if blood is negative and mosaicism is suspected;
- evaluate first-degree relatives.
- Brain:
- MRI (tubers, subependymal nodules, SEGA, ventricles);
- EEG, with prolonged video-EEG if seizures are suspected;
- TAND screening (TAND checklist) and a baseline developmental or neuropsychological assessment.
- Eye: dilated ophthalmologic examination, with a baseline before vigabatrin.
- Heart:
- echocardiogram, especially under age 3;
- ECG for conduction defects.
- Kidney:
- abdominal MRI (angiomyolipomas, cysts);
- blood pressure and renal function (GFR).
- Lung:
- high-resolution chest CT for females 18 and older, and anyone with respiratory symptoms;
- pulmonary function tests if LAM is found.
- Skin and teeth: dermatology and dental examination.
Ongoing surveillance (GeneReviews)
- Brain:
- brain MRI every 1–3 years until age 25. People with asymptomatic childhood SEGAs keep periodic imaging into adulthood, and growing SEGAs are imaged more often.
- EEG in infants every 6 weeks up to 12 months, then every 3 months up to 24 months, and as needed after that.
- TAND screening at least annually, with a full evaluation at key developmental stages.
- Kidney:
- abdominal MRI every 1–3 years;
- GFR and blood pressure at least annually.
- Heart: echocardiogram every 1–3 years in asymptomatic children with rhabdomyomas, until they regress.
- Lung:
- LAM symptom screening at each visit in adult women;
- HRCT every 5–7 years in asymptomatic women without cysts, from 18 through menopause.
- Eye: annual ophthalmology, and vision testing on vigabatrin.
- Skin and teeth:
- annual dermatology;
- dental review every 6 months, with panoramic radiographs by age 7.
Where mTOR inhibitors fit
- Everolimus or sirolimus have randomized evidence for:
- SEGA (EXIST-1) ;
- refractory focal seizures (EXIST-3) ;
- renal angiomyolipoma (EXIST-2) ;
- LAM (MILES) ;
- topical use for facial angiofibromas (TREATMENT) .
- Suppression lasts only as long as treatment. Regrowth after stopping, and the return of lung decline after stopping, suggest therapy must be continued .
Related topics
- SEGA: Management: growth, surgery and everolimus.
- Drug-Resistant Epilepsy in TSC: surgical options for TSC seizures.
- Cowden Syndrome: another hamartoma syndrome on the mTOR pathway.
- Neurofibromatosis: another neurocutaneous syndrome.
- Focal Cortical Dysplasia: overlapping cortical malformation biology.
- Hemispherectomy in Children: surgery for hemispheric TSC epilepsy.
- Laser Interstitial Thermal Therapy (LITT) in Epilepsy Surgery: laser ablation of epileptogenic tubers.
References
- Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
- Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. In: Adam MP, et al., eds. GeneReviews. Seattle (WA): University of Washington, Seattle; 1999 (updated 2024). PMID 20301399. verified
- Kingswood JC, d'Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA): baseline data on 2093 patients. Orphanet J Rare Dis 2017;12(1):2. doi:10.1186/s13023-016-0553-5. PMID 28057044. verified
- Jansen AC, Belousova E, Benedik MP, et al. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex. Front Neurol 2019;10:705. doi:10.3389/fneur.2019.00705. PMID 31333563. verified
- Farach LS, Richard MA, Wulsin AC, et al. Drug-resistant epilepsy in tuberous sclerosis complex is associated with TSC2 genotype: more findings from the Preventing Epilepsy Using Vigabatrin (PREVeNT) trial. Pediatr Neurol 2024;159:62–71. doi:10.1016/j.pediatrneurol.2024.06.012. PMID 39142021. verified
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304–314. doi:10.1002/ana.25956. PMID 33180985. verified
- Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol 2018;154(7):773–780. doi:10.1001/jamadermatol.2018.0464. PMID 29800048. verified
- Öhnell HM, Kjellström U, Eklund E, et al. Ophthalmic manifestations in children with tuberous sclerosis complex. Acta Ophthalmol 2024;102(4):421–427. doi:10.1111/aos.15812. PMID 37991117. verified
- Craig K, Patel J, Murphy D, et al. Paediatric cardiac tumours: a national population study. Pediatr Cardiol 2026;47(3):1200–1208. doi:10.1007/s00246-025-03893-7. PMID 40366416. verified
- Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817–824. doi:10.1016/S0140-6736(12)61767-X61767-X). PMID 23312829. verified
- McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364(17):1595–1606. doi:10.1056/NEJMoa1100391. PMID 21410393. verified
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132. doi:10.1016/S0140-6736(12)61134-961134-9). PMID 23158522. verified
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-231419-2). PMID 27613521. verified
- Tran LH, Zupanc ML. Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature. Pediatr Neurol 2015;53(1):23–30. doi:10.1016/j.pediatrneurol.2014.10.024. PMID 26092412. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed.
- Reference 2 (GeneReviews, an NCBI book with no DOI) was checked through its Europe PMC summary, which is the source for the organ-system list, inheritance, management and surveillance intervals.
- Numbers were checked against the PubMed abstracts and that summary.
Caveats:
- The individual major and minor criteria (with their counts and sizes) follow the 2021 criteria (reference 1). Its abstract and the GeneReviews summary give only the "2 major or 1 major + 2 minor" rule, so the itemized list is standard teaching that should be checked against the reference 1 full text.
- The following are standard teaching, not drawn from the cited abstracts:
- the gene locations and product names;
- the mosaicism testing advice;
- the TSC2–PKD1 contiguous gene syndrome;
- ECG for conduction defects;
- echocardiography under age 3;
- pulmonary function tests;
- the TAND checklist name;
- Wood's lamp;
- liver angiomyolipomas as an example;
- infantile spasms as the classic early presentation;
- hydrocephalus from SEGA;
- LAM rising with age;
- prenatal rhabdomyoma as the first clue to TSC.
- The "workup at diagnosis" list is a synthesis of the baseline recommendations; reference 2's summary details surveillance rather than baseline testing.
- References 10 and 11 enrolled adults.
- The figure is an original schematic.